Home Procurement NewsEli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer’s drugs

Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer’s drugs

September 12, 2024•

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily to increase production.

Was this article helpful?

YesNo

Last modified: September 12, 2024

Previous: Moderna to cut $1.1 billion in costs and launch 10 new products by 2027 as it charts post-Covid future

Next: Junior Bridgeman buying stake in Milwaukee Bucks in a deal that values team at $4 billion

Are you ready to join the Community?

Join the Conversation!

Community of Practice Portal aims to bring together key stakeholders in the procurement landscape in Nigeria to leverage on each others skillset in relation to understanding Procurement data in a bid to use these data to create stories and to generate action from the government.

Community of practice platform is an initiative under Anti-Corruption Innovation Project, a UNDP funded Project in collaboration with Accountability lab Nigeria, and Open Contracting Partnerships